首页 / 院系成果 / 成果详情页

New strategies for targeting drug combinations to overcome mutation-driven drug resistance 期刊论文

编号：

fe71d9f8-a19d-43a0-86c3-c11e7d9d7552
作者：

Wang, Linyan^[1] Wang, Haiyun^[2] Song, Dongli^[1] Xu, Menglin^[1] Liebmen, Michael^[1]
语种：

English
期刊：

SEMINARS IN CANCER BIOLOGY ISSN：1044-579X 2017 年 42 卷 (44 - 51) ; FEB
收录：
关键词：

Drug resistance Lung cancer Precision medicine Pharmacogenomics profile CRISPR-Cas9 screening Pathway-centric therapy
摘要：

Targeted therapies are suggested as an effective alternative for patients with cancer that harbor mutations, but treatment outcomes are frequently limited by primary or acquired drug resistance. The present review describes potential mechanisms of primary or acquired drug resistances to provide a resource for considering how to be overcome. We focus on strategies of targeted drug combinations to minimize the development of drug resistance within the context how resistance develops. Strategies benefit from the combined use of "omics" technologies, i.e., high-throughput functional genomics data, pharmacogenomics, or genome-wide CRISPR-Cas9 screening, to analyze and design targeted drug combinations for mutation-driven drug resistance. We also introduce new insights towards pathway-centric combined therapies as an alternative to overcome the heterogeneity and benefit patient prognoses. (C) 2016 Elsevier Ltd. All rights reserved.
推荐引用方式
GB/T 7714：

Wang Linyan,Wang Haiyun,Song Dongli, et al. New strategies for targeting drug combinations to overcome mutation-driven drug resistance [J].SEMINARS IN CANCER BIOLOGY,2017,42:44-51.
APA：

Wang Linyan,Wang Haiyun,Song Dongli,Xu Menglin,&Liebmen Michael.(2017).New strategies for targeting drug combinations to overcome mutation-driven drug resistance .SEMINARS IN CANCER BIOLOGY,42:44-51.
MLA：

Wang Linyan, et al. "New strategies for targeting drug combinations to overcome mutation-driven drug resistance" .SEMINARS IN CANCER BIOLOGY 42(2017):44-51.

浏览次数：3  下载次数：0

分享到：

浏览次数：3

下载次数：0

打印次数：0